[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"photoaging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:photoaging":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100635355","study-of-rrs-ha-long-lasting-for-improving-facial-wrinkles-and-skin-quality-100635355",false,"NCT07551609","Study of RRS® HA Long Lasting for Improving Facial Wrinkles and Skin Quality","Post-Market Interventional Clinical Investigation to Evaluate the Safety and Efficacy of RRS® HA Long Lasting for the Improvement of Facial Wrinkles and Skin Quality","ORACLE LL","Inclusion Criteria:\n\n* Subject has presence of grade 2 (moderate) or grade 3 (severe) wrinkles according to SASSQ. The Investigator evaluates the wrinkles on both sides of the face as grade 2 or 3 SASSQ;\n* Subject has mild to moderate photoaging according to Alexiades-Armenakas scale;\n* Subject is willing and able to provide informed consent and attend follow-up visits;\n* Subject is psychologically able to understand the study related information and to give a written informed consent (ICF);\n* Subject has voluntarily provided written informed consent to participate in the study, and use of data privacy (sign the EC approved ICF), prior to any study-related procedure being performed;\n* Subject is aged \\>18 years;\n* Subject is seeking correction of his\u002Fher facial wrinkles, agrees with recommendation by the Investigator, and has a reasonable expectation of the treatment effect;\n* Subject accepts the obligation not to receive any other facial procedures or treatments impacting facial wrinkles at any time during the study (before their study exit);\n* Subject is able to follow study instructions and likely to complete all required visits, as assessed by the Investigator, agree to maintain existing skincare habits during the trial period;\n* Female of childbearing potential (who are sexually active, who do not have primary ovarian insufficiency, have not undergone hysterectomy or bilateral tubal ligation, who are not postmenopausal for at least 1 year) must have a negative urine pregnancy test (UPT) at screening (or prior to treatment on Visit 1) and Visit 3 (in case of touch-up treatment) and use a medically accepted contraceptive regimen (self-reported) since at least 12 weeks before the beginning of the study and during the study.\n\nExclusion Criteria:\n\nIn terms of population:\n\n* Subject is a pregnant or breastfeeding woman, or planning a pregnancy during the study;\n* Subject has scars, moles, tattoo, or anything on the face which might interfere with the evaluation;\n* Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship;\n* Subject in a social or sanitary establishment;\n* Subject participating to another research on human beings or who is in an exclusion period of one month from a previous study;\n* Subject needs to long-term outdoor work or long-term exposure to sunlight after treatment;\n* Subjects who intend to initiate or continue any intentional weight-loss program (including diet, medication, or increased physical activity) during the study period;\n* Subject has an adequate understanding of skin care after the treatment sessions: avoiding sun exposure, extreme temperature (sauna, hammam, etc.) or any source of UV rays 24 hours after the product application.\n\nIn terms of associated pathology:\n\n* Subject presenting any symptom which can be related to a medical condition that is likely to make the subject not being compliant with the study schedule, at the discretion of the Investigator;\n* Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results;\n* Subject with known history of or suffering from autoimmune disease and\u002For immune deficiency, active connective tissue disorder (e.g., arthritis rheumatoid, scleroderma, and systemic lupus erythematosus), cancer, or receiving immunomodulatory agents;\n* Subject suffering from active inflammatory and\u002For infectious cutaneous disorders in or near the studied zones (e.g. herpes, acne). Subject with recurrent herpes in the wrinkle area is not eligible even if asymptomatic at time of inclusion;\n* Subject with a history of streptococcal disease, such as acute rheumatic fever or recurrent sore throats with cardiac localization;\n* Subject prone to develop inflammatory skin conditions or having tendency to bleeding disorders;\n* Subject having history of allergy or anaphylactic shock including hypersensitivity to hyaluronic acid or any of the other device components of the product or local anesthetic cream;\n* Subject with a tendency to develop keloids or hypertrophic scars, or clinically significant skin pigmentation alterations.\n\nRelating to previous or ongoing treatment:\n\n* Subject participated in another clinical study in the last 30 days;\n* Subject having received facial treatment with a laser, a dermabrasion, a surgery, a peeling, or other ablative procedure within the past 6 months prior to inclusion;\n* Subject having received injection with a resorbable filling product in the face within the past 24 months prior to inclusion;\n* Subject having received at any time injection with a slowly resorbable filling product (e.g. polylactic acid, calcium hydroxyapatite, combinations of HA and Hypromellose) or with a non-resorbable filling product (e.g. polyacrylamide or silicone);\n* Subject having received at any time a treatment with tensor threads in the face;\n* Subject currently undergoing or planning to undergo dental procedures that affect facial observation during the study (e.g., orthodontics, tooth extraction, dental implantation, etc.);\n* Subjects having received surgical rhinoplasty procedure at any time;\n* Subject under medications which may cause lipo-atrophy (e.g. Ozempic);\n* Subject using medication such as aspirin, NSAIDs (e.g. ibuprofen), antiplatelet agents, anticoagulants, vitamin C within one week prior to inclusion or being a chronic user of anticoagulant treatment;\n* Subject undergoing a topical treatment on the test area or a systemic treatment:\n* Antibiotics and antihistamines during the 2 weeks prior to study start;\n* Immunosuppressors and\u002For corticoids during the 3 months prior to study start;\n* Retinoids during the 6 months prior to study start.","ALL","18 Years",{"count":20,"type":21},207,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this clinical study is to confirm the clinical performance and long-term safety of the CE-marked RRS® HA Long Lasting in the treatment of skin photoaging and its consequences, with a primary focus on improving facial wrinkles and skin quality in healthy adults.\n\nThe main questions it aims to answer are: the proportion of responders achieving a clinically significant change in facial wrinkles from baseline to Month 2 on both sides of the face; improvement in photodamage compared to the control group at 2 months. Researchers will compare the group treated with RRS® HA Long Lasting to an untreated control group to evaluate the product's effectiveness in improving facial wrinkles and skin quality.",[27,28,29,30],"Photoaged Facial Skin","Photoaging","Wrinkle Reduction","Skin Quality Improvement",[32],"photoaging, hyaluronic acid, wrinkles, skin quality","RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2026-04-26",{"date":41,"type":21},"2028-03-30",{"name":43,"class":44},"Skin Tech Pharma Group S.L.U.","INDUSTRY",5,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100531116","investigating-age-dependence-of-fibroblast-and-extracellular-matrix-responses-to-cross-linked-hyaluronic-acid-filler-in-human-skin-100531116","NCT06195605","Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin","Inclusion Criteria:\n\n* Subjects must understand and sign the informed consent prior to participation\n* Subjects must be in generally good health\n* Subjects must be able and willing to comply with the requirements of the protocol\n\nExclusion Criteria:\n\n* Pregnant, plan to become pregnant during the study, or are nursing a child. Participants will be asked to self-report pregnancy\n* Individuals with bleeding disorders\n* Tend to heal poorly or form very thick scars called keloids\n* Have a lidocaine sensitivity, including those with epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction.\n* Individuals with active inflammation or infection of the skin, including active herpes infection.\n* Have a significant medical history or concurrent condition which the investigator(s) feel is not safe for study participation, including history of frequent herpes infections, and subjects planning to be exposed to excessive sun, Ultraviolet lamps and extreme cold weather during the first week after injection.\n* History of allergies to gram positive bacterial proteins\n* Individuals with who have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet aggregation in the preceding 3 weeks.\n* Have an active inflammation or infection of the skin near the site of injection\n* Are taking any medications that suppress your immune system\n* Have severe allergies to medications or other things that we believe might make participation unsafe for you\n* Have a history of connective tissue diseases, such as:\n\n  * rheumatoid arthritis\n  * scleroderma\n  * polymyositis\u002Fdermatomyositis\n  * systemic lupus erythematosus (SLE)","30 Years","50 Years",{"count":55,"type":21},15,[24],"The purpose of the study is to investigate the impact of the injection of dermal filler on the quality of the skin dermal extracellular matrix in persons between the ages of 30-50 years. The quality of the dermal extracellular matrix will be assessed following injection of dermal filler compared to injection of saline vehicle.",[28],[60,61,62],"Extracellular matrix","Hyaluronic acid","dermal filler","2025-07-02",{"date":65,"type":37},"2025-07-08",{"date":67,"type":37},"2024-05-09",{"date":69,"type":21},"2026-11",{"name":71,"class":72},"University of Michigan","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":73},"100550868","platelet-rich-fibrin-versus-platelet-rich-plasma-for-microneedling-treatment-of-facial-photoaging-100550868","NCT06452667","Platelet Rich Fibrin Versus Platelet Rich Plasma for Microneedling Treatment of Facial Photoaging","Platelet Rich Fibrin Versus Platelet Rich Plasma for Microneedling Treatment of Facial Photoaging-a Double Blind Randomized Controlled Study","Inclusion Criteria:\n\n1. Men or female patients older than 20 years old with facial photoaging (Glogau Scale type II)\n2. The photoaging severity of bilateral face is symmetric.\n\nExclusion Criteria:\n\n1. Patients with thrombocytopenia, coagulopathy, hematopoietic malignancy.\n2. Patients with severe inflammation over treated area, malignancy, keloid, or poor wound healing history.\n3. Patients had received laser, radiofrequency, ultherapy over treated area within 6 months.\n4. Patients had received botulism or filler injection over treated area within 12 months.\n5. Patients had received plastic surgery over treated area within 12 months.\n6. Patients had severe psychiatric disorders with poor control.\n7. Patients with other diseases which are not suitable for receiving platelet rich plasma (PRP) or platelet rich fibrin (PRF) therapy.",true,"20 Years",{"count":84,"type":21},30,[24],"The present study was conducted for analyzing the efficacy and safety of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in photoaging therapy.\n\nSpecific arms:\n\n1. The investigators will compare the photoaging improvement of PRF and PRP treated face before and after treatment by two blinded investigators.\n2. The investigators will evaluate the improvement of each parameter of photoaging by Visia system, dermoscope, and optical coherence tomography.\n3. The investigators will evaluate the safety of the treatment of PRF and PRP.\n\nEach case will receive 3 sessions of injection therapies with one month interval (T0, T1, and T2). Each case will receive PRP therapy on one side of the face and PRF on the other side of face. The investigators will determine the treatment method for both sides of each case randomly by coin flapping before the study. The investigators will evaluate each case before each session of therapy (T0, T1, T2) as well as 1 (T3) and 3 months (T4) after final session of treatment.",[28],[89,90,91],"photoaging","platelet rich plasma","Platelet rich fibrin","NOT_YET_RECRUITING","2024-06-05",{"date":95,"type":37},"2024-06-11",{"date":97,"type":21},"2024-06-01",{"date":99,"type":21},"2025-05-31",{"name":101,"class":72},"Chang Gung Memorial Hospital"]